Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
It would be the first protein-based alternative available in Israel
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
It’s a two-dose vaccine administered 28 days apart
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Subscribe To Our Newsletter & Stay Updated
